Stephen Fesik Archives
Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancer
Mar. 14, 2018—New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.
Jun. 23, 2016—Vanderbilt University has been selected as one of seven Dedicated Centers in the nation for the next phase of the Chemical Biology Consortium (CBC), a national network of scientists on the leading edge of cancer drug discovery.
May. 19, 2016—A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures.
Mar. 26, 2015—Vanderbilt University researchers have discovered a cleft in a chromosome-binding protein that may hold the key to stopping most cancers in their tracks.
Jan. 29, 2015—The Lustgarten Foundation has awarded a $1.5 million Research Investigator Grant to Stephen Fesik, Ph.D., professor of Biochemistry, Pharmacology and Chemistry, for research designed to discover new drugs for the treatment of pancreatic cancer.
Mar. 19, 2012—The April program for My Health Chat will be the promising world of cancer drug discovery. Panelists will be Lawrence Marnett, director of the Vanderbilt Institute of Chemical Biology, and Stephen Fesik, director of drug discovery at Vanderbilt-Ingram Cancer Center. They will discuss and take questions regarding how information about the genetic drivers of cancer...
Jan. 12, 2011—Seven Vanderbilt University faculty members have been elected fellows of the American Association for the Advancement of Science, an honor bestowed upon them by their AAAS peers. They are among 503 AAAS members from around the country who achieved this honor because of their distinguished efforts to advance science or its applications. The newest AAAS...